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Malignant Hyperthermia (MH)
• According to the
International
Classification of Diseases,
MH is a rare, but
progressive, and lifethreatening hyperthermic
reaction following the
administration of general
anesthesia (Hopkins et. al.,
2020)
• With early detection and
intervention MH can be
treated. Without
immediate treatment
mortality rate is
significantly higher (Yang
et. al., 2020).

Why MH?

•

•
•

MH can happen at any age,
but it tends to happen
more often in young adults
and children (Gupta &
Hopkins, 2017).
MH is a disease process
that although rare can
become fatal quickly.
The mortality from MH is
approximately 6 to 12% in
the United States (Gupta &
Hopkins, 2017)

Signs & Symptoms
•

•

•

The most common
diagnostic characteristics
of MH include unexplained
rise in ETCO2, increase in
heart rate, and a rapid
increase in temperature.
Others include masster
spasm, muscle rigidity,
dark colored urine, and
sweating.
Family history of MH is an
important indicator.
(Yang et. al., 2020)

Pathophysiology
MH is an autosomal dominate
genetic disorder of the
skeletal muscle resulting in a
hyperthermic reaction to a
trigger such as violate
anesthetic gases or the
depolarizing neuromuscular
blocking agent,
Succinylcholine.
• In a patient who
experiences MH, there is
genetic issues with the
calcium channels in
skeletal muscle.
• Predominately mutations
in the ryanodine receptor
type 1 (RYR1) gene.
• There are currently 29
known mutations in the
RYR1 gene.
• This mutation causes the
actin–myosis–troponin
interaction to occur
leading to muscle
contraction, ultimately
being the cause of the
hypermetabolic response.
• In MH, the relaxation of
muscle is inhibited, but
calcium is continuously
released causing nonstop
muscle contraction.
(Haili & Weant, 2021)

Clinical Significance
Published data of MH incidence
is more than likely
underreported than what is
seen in literature.
• MH is typically more
common in males, with
males making up about 68%
of cases.
• Any age, race, gender, or
ethnicity can be at risk.
• The mean age for reported
MH cases is 21 to 23 years
old.
• MH tends to occur after
more then one exposure of
anesthesia but can occur on
the first exposure to a
triggering agent.
• Patients under the age 15
make up about 52% of the
cases of MH.
• Recent studies show that
the genetic mutation in the
RYR1 gene is about 1 in
2,000 to 1 in 3,000
frequency.
(Malignant hyperthermia
(NORD), 2013)
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Early identification and Intervention is key to patient survival
• Once MH is suspected the anesthesia provider must stop the
administration of the inhaled anesthetic and begin to
hyperoxygenate the patient at 100% FiO2.
• Begin the administration of the medication Dantrolene
following the guidelines.
• Actively being cooling measure to get patient’s core body
temperature lowered.
• If not already present, establish invasive monitoring devices to
monitor for hemodynamic stability.
• Collect routine lab work, watching closely for hyperkalemia,
acidosis, and indicators of renal injury.
• Once the patient is medically stable, transfer to the critical care
unit for further treatment and observation
(Gupta and Hopkins, 2017)

Complications

Nursing Care
Once Malignant Hyperthermia is
suspected many nursing interventions
need to happen quickly in order to
reverse the deadly cascade that can
ensue with MH.
•
Registered Nurses as well as
Certified Registered Nurse
Anesthetists (CRNA) should be
educated on MH signs and
symptoms.
•
Nurses working in the Post
Anesthesia Care Unit (PACU), the
operating room (OR), and the
intensive care units (ICU) should be
specially trained because these
environments are where MH is
most likely to occur due to the
medications and anesthetic gas
administered.
•
If a nurse suspects MH, 100%
oxygen should be started via a
nonrebreather mask if not
mechanically ventilated in the OR.
•
The provider and anesthesia should
be notified immediately, and
someone should retrieve the MH
chart.
•
The primary nurse should stay at
bedside with the patient and
monitor vitals signs via cardiac
monitors.
•
The IV lines should be checked to
verify patency so that the
medications can be administered
once available.
•
Take measures to reduce body
temperature such as removing
extra sheets, cool IV fluids, ice
packs, or a cooling blanket.
•
Place a foley catheter to monitor
kidney function.
•
Draw frequent labs to monitor
electrolytes, pH, and renal function.
•
Once the patient has been stabilized
and transferred to the ICU,
Dantrolene will continue to be
administered every 4 to 6 hours for
the next 24 to 48 hours to prevent
recurrent MH episode.
•
Before discharge from the hospital
the nurse should educate the
patient on their new medical
history and explain the importance
of making medical providers and
family aware to prevent future
episodes.
•
Provide the patient with written
information about MH and
resources to learn more.
(Wolter Kluwer, 2006)

•

•

•

•

•

Complications associated
with MH come from the
exposure of the triggering
agent that leads to
uncontrolled release of
calcium from the skeletal
muscles (Haili & Weant,
2021).
The continuously muscle
contraction causes
“increased CO2 production
as a by-product of ATP
generation in the
mitochondria, excess heat
production from the rapid
consumption of ATP, and
increased lactate
production as the body
attempts to produce
energy by anaerobic
metabolism “ (Haili &
Weant, 2021).
These each lead to cell
destruction releasing high
levels of potassium and
creatine kinase into the
blood stream which
potentially can cause
cardiac arrythmias or
renal failure (Haili &
Weant, 2021).
Calcium Channel blockers
should be avoided when
administering Dantrolene
because together they can
cause hyperkalemia which
can lead to cardiac
dysrhythmias or cardiac
arrest. (Wolters Kluwer,
2006)
Another potential
complication can be
disseminated
intravascular coagulation
(DIC) (Wolters Kluwer,
2006)

•

•

Conclusions

Since MH is a fast
progressing, lethal disease
process, “The Malignant
Hyperthermia Association
of the United States
(MHAUS) guidelines state
that dantrolene must be
available within 10min of
the decision to treat MH at
all anesthetizing/ sedating
locations where MHtriggering agents are used.
until adequate response is
achieved. MHAUS
mandates that each
institution stock at
least 720mg of
dantrolene—sufficient to
administer 10mg/kg to a
70-kg patient” (Larach et.
al., 2019)
Any health care provider
in an environment where
MH is possible, must be
educated and aware of MH
signs and symptoms and
treatment in order to act
quickly to save the
patient.
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